Tiziana announces development plans for foralumab
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
List view / Grid view
News
Shire to acquire Baxalta in $32 billion deal
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
AbbVie initiates Phase 3 studies for pan-genotypic HCV regimen
11 January 2016 | By Victoria White
AbbVie's investigational HCV regimen, combining ABT-493 and ABT-530, will be evaluated in patients with genotypes 1-6 chronic HCV infection...
Incyte and AstraZeneca announce new lung cancer trial collaboration
11 January 2016 | By Victoria White
Incyte and AstraZeneca are to evaluate the efficacy and safety of Incyte's INCB39110 in combination with AstraZeneca's Tagrisso (osimertinib) as a second-line treatment for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), who have been treated with a first generation EGFR tyrosine kinase inhibitor (TKI) and subsequently developed the…
Early immune effect of SCIB1 observed by ImmunTraCkeR diagnostic
11 January 2016 | By Victoria White
Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions...
Moberg announces positive data for BUPI in oral mucositis
11 January 2016 | By Victoria White
Oral mucositis is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy...
ViiV and Janssen progress two drug injectable HIV-1 treatment
8 January 2016 | By Victoria White
ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine...
Roche presents updated results for atezolizumab in mUC
8 January 2016 | By Victoria White
Median overall survival from the updated study results was 11.4 months in people with higher levels of PD-L1 expression, and 7.9 months in the overall study population...
Vasculitis treatment market to expand in value to $558m by 2024
8 January 2016 | By Victoria White
GlobalData states that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis...
X2 series balances innovative functional solutions
7 January 2016 | By RADWAG
The X2 series embodies synergy between conventional solutions characteristic for high quality balances, and technology intended mainly for professional standards...
Positive top-line results from the Japanese Phase II study of Traumakine for the treatment of ARDS
7 January 2016 | By Nicholas Jackson
Faron has announced that its Japanese licensing partner Maruishi has obtained positive results from the Phase II Japanese study for Traumakine conducted by Maruishi in Japan...
Positive top-line Phase IIa trial results for DS107 as a treatment for atopic dermatitis
7 January 2016 | By Nicholas Jackson
DS Biopharma has announced positive top-line Phase IIa trial results for DS107 as an oral treatment for moderate to severe atopic dermatitis...
Innovative blood test can be used as a predictive tool for preeclampsia
7 January 2016 | By Nicholas Jackson
PROGNOSIS study published in the New England Journal of Medicine reveals that an innovative Roche blood test can be used as a predictive tool for preeclampsia...
Phase 1 study of Verastem’s FAK inhibitor, VS-6063, starts
6 January 2016 | By Victoria White
The Phase 1 study, initiated by Washington University, will evaluate VS-6063 in combination with pembrolizumab and gemcitabine in patients with pancreatic cancer...
Pharming completes patient enrolment in Phase 2 Ruconest trial
6 January 2016 | By Victoria White
Pharming has completed patient enrolment in the Phase 2 clinical study of Ruconest (recombinant C1 esterase Inhibitor, 50 IU/kg) for prophylaxis in patients with hereditary angioedema (HAE).
